.Attributes Medication, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of individuals along with HER2+ sophisticated breast cancer cells and also active or secure human brain metastases presented consistent intracranial task and wide spread effectiveness of T-DXd.